Actualités sur Health

31.08.2012 – 10:45
Janssen-Cilag International NV (Janssen)
Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part ...
plus
28.08.2012 – 14:03
Resverlogix Corp.
Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
Munich And Calgary, Alberta (ots/PRNewswire) - -- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period -- -- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque -- TSX Exchange Symbol: RVX Resverlogix Corp. today announced that the ...
plus
28.08.2012 – 09:02
Boston Scientific
PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval as MRI Conditional
Paris (ots/PRNewswire) - Boston Scientific Corporation has received CE Mark approval for use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System in patients with the system and are in need for magnetic resonance imaging (MRI) head-only scans. The PRECISION PLUS SCS System is the world's first rechargeable SCS device. This approval provides physicians with an ...
plus
27.08.2012 – 09:01
Boston Scientific
PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation
Paris (ots/PRNewswire) - Boston Scientific Corporation has received CE Mark approval for use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System, the world's first rechargeable SCS device, in peripheral nerve stimulation for patients with chronic intractable pain of the trunk. Peripheral nerve stimulation ...
plus
23.08.2012 – 21:07
Pivotal Therapeutics Inc
Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company will be exhibiting at the European Society of Cardiology (ESC) Congress 2012 in Munich, Germany August 25-29, 2012, Hall A2 Booth #B440. The ESC ...
plus
22.08.2012 – 06:57
LifeWatch AG
EANS-Adhoc: LifeWatch AG: Results for the second quarter 2012 confirm turnaround (with document)
http://resources.euroadhoc.com/us/8OrWIbpx http://resources.euroadhoc.com/us/9qJNp19Q issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 ...
2 Documents
plus
20.08.2012 – 10:01
UBM Live
UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Frankfurt, Germany (ots/PRNewswire) - In June UBM signed a partnership agreement with The Swiss Import Promotion Programme (SIPPO), a performance mandate of SECO implemented by the foreign promotion department of OSEC, with the aim of increasing the competitiveness of small and medium size enterprises from emerging markets in developing countries. Through their ...
plus
16.08.2012 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch to report on First Half Year and Second Quarter 2012 Results on August 22, 2012 (with document)
http://resources.euroadhoc.com/us/QBMtg1Sc http://resources.euroadhoc.com/us/wgWZpOYn issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
2 Documents
plus
13.08.2012 – 22:12
Mars Incorporated
Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults
Germantown, Maryland (ots/PRNewswire) - A study conducted by researchers from the University of L'Aquila in Italy and Mars, Incorporated provides compelling new evidence that the regular consumption of dietary cocoa flavanols may improve cognitive function in elderly subjects with early memory decline. Just published online in the journal Hypertension, this current ...
plus
09.08.2012 – 22:47
Pivotal Therapeutics Inc
Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN? Unique Formulation
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce that data from a scientific study related to the company's product VASCAZEN(TM) concluded that highly purified Eicosapentaenoic ...
plus
09.08.2012 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch to report on First Half Year and Second Quarter 2012 Results on August 22, 2012 (with document)
http://resources.euroadhoc.com/us/hAV9r7TT http://resources.euroadhoc.com/us/6L9y8D5x issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
2 Documents
plus
31.07.2012 – 14:48
Milner Foundation
New Annual US$3 Million Fundamental Physics Prize Recognizes Transformative Advances in the Field
Moscow (ots/PRNewswire) - Inaugural nine recipients of the Prize receive US$27 million in aggregate, all of whom agree to form a Selection Committee to award future prizes The Milner Foundation announces today the launch of the Fundamental Physics Prize Foundation, a not-for-profit corporation ("Foundation") ...
plus
27.07.2012 – 11:41
Brainlab AG
CORRECTION - Brainlab: Enhanced Patient Positioning System Unveiled Further Refining Image Guided Radiation Therapy (IGRT)
Chicago (ots/PRNewswire) - In the news release, "Enhanced Patient Positioning System Unveiled Further Refining Image Guided Radiation Therapy (IGRT)" issued on 27 Jul 2012 06:00 GMT, by Brainlab over PR Newswire, due to an error by PR Newswire there was a formatting problem with the references. Cone beam CT ...
plus
27.07.2012 – 08:02
Brainlab AG
Enhanced Patient Positioning System Unveiled Further Refining Image Guided Radiation Therapy (IGRT)
Chicago (ots/PRNewswire) - Brainlab releases an advanced version of the ExacTrac Patient Positioning system after more than one million frameless treatments Today, Brainlab officially unveils the new ExacTrac(R)6.0 Patient Positioning system, delivering key improvements for both frameless radiosurgery and ...
plus
25.07.2012 – 01:03
The World Hepatitis Alliance
World Hepatitis Alliance Welcomes New Global Framework Aimed at Saving the Lives of Millions Living With Hepatitis
Geneva (ots/PRNewswire) - Alliance calls on governments to support the WHO strategy by setting regional targets to eradicate this killer disease The World Hepatitis Alliance have today welcomed the launch of the World Health Organization (WHO) framework for hepatitis as the global patient community marks World ...
plus
24.07.2012 – 01:04
Eisai Europe Limited
First Clinical Data for BACE Inhibitor E2609 Showcased at International Alzheimer's Conference
Hatfield, England (ots/PRNewswire) - Eisai's new investigational molecule discovered and developed collaboratively in the UK and Japan Eisai in Europe today releases the first clinical data for E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor, presented during oral sessions at the ...
plus
19.07.2012 – 12:48
CPhI Conferences India
Insights on Regulatory, QbD and Formulation of Nano Medicines at Nano Suspensions India 2012
Hyderabad, India (ots/PRNewswire) - CPhI introduces Nano Suspensions India 2012 [http://ubmindia.co.in/cgi-bin18/DM/t/hzOj0dsj5Y0KYO0J7160EG ] which will be focusing on the most relevant and pressing issues around regulatory, QbD, solubility, stability and efficient scale-up of nano medicines. Taking place on 21-22 August 2012 at Fortune Select Manohar, Hyderabad, ...
plus
13.07.2012 – 08:03
Nordic Group BV
The Nordic Group Acquires Rights to Trasylol® From Bayer HealthCare
Hoofddorp, Netherlands (ots/PRNewswire) - Nordic Group announced today that it has reached an agreement with Bayer HealthCare in which Nordic will acquire Trasylol(R) (aprotinin injection) worldwide excluding the United States. Under this agreement, Nordic will become the Marketing Authorization Holder for aprotinin in the relevant Territories. This follows the opinion ...
plus
10.07.2012 – 21:38
Cryo-Save AG
Cryo-Save Arabia now U.S. Food and Drug Administration (FDA) Registered
Zutphen, The Netherlands (ots/PRNewswire) - Cryo-Save Arabia's lab, located in Dubai, is now U.S. Food and Drug Administration (FDA) registered for autologous and family-related use of umbilical cord blood stem cells. This important accreditation confirms again the quality and high standards that are key to Cryo-Save. It is with great excitement that Cryo-Save Arabia, ...
plus
10.07.2012 – 01:35
Eisai Europe Limited
Eisai Expands in Israeli Market With Approval of Halaven
Hatfield, England (ots/PRNewswire) - Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from ...
plus
10.07.2012 – 01:34
Eisai Europe Limited
New Breast Cancer Treatment Available in France
Hatfield, England (ots/PRNewswire) - Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior ...
plus
10.07.2012 – 01:33
Eisai Europe Limited
Eisai Announces Preliminary Results of Phase III Study of Halaven® (Eribulin) in Locally Advanced or Metastatic Breast Cancer
Hatfield, England (ots/PRNewswire) - Eisai Europe Limited today announces preliminary results from a recently completed Phase III study (Study 301) comparing Halaven(R) (eribulin) and Xeloda(R) (capecitabine). The study enrolled women with locally advanced or metastatic breast cancer in an earlier line of treatment ...
plus
03.07.2012 – 07:02
Cryo-Save AG
Cryo-Save's Cost-Free Donation Programme Serves Families in Need
Zutphen, The Netherlands (ots/PRNewswire) - Free of charge, Cryo-Save's programme gives the opportunity to treat a family member diagnosed with a life-threatening disease treatable with stem cells. Cryo-Save, the leading international family stem cell bank, shows continuous commitment to its corporate social responsibility programme. Family and children's health is the company's number one priority. The Cryo-Save ...
plus
28.06.2012 – 13:11
LifeWatch AG
EANS-Adhoc: Annual General Meeting of LifeWatch AG (with document)
http://resources.euroadhoc.com/us/HC3mrSSV issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Un document
plus
28.06.2012 – 12:17
Shire Pharmaceuticals Group Plc
Shire's VPRIV® (velaglucerase alfa for injection) Shows Significant Improvement in Gaucher-Related Bone Disease
Nyon, Switzerland (ots/PRNewswire) - - In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9 months Shire plc , the global specialty biopharmaceutical company, today presented ...
plus
27.06.2012 – 06:57
LifeWatch AG
EANS-Adhoc: LifeWatch V: State-of-the-art smartphone with healthcare capabilities empowering patients and consumers (with document)
http://resources.euroadhoc.com/us/19lpaarY issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
27.06.2012 – 01:03
Eisai Europe Limited
Eisai Enters Russian Market With Approval of First Product
Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) set to offer new option for epilepsy treatment in Russia Eisai, one of the world's leading research-based pharmaceutical companies, announces the expansion of its operations into Russia, with the approval of its first product - the epilepsy treatment, Zonegran(R) (zonisamide). Eisai's entry into the Russian healthcare marketplace is part of the company's plan ...
plus
22.06.2012 – 15:02
LifeWatch AG
EANS-News: LifeWatch AG / (with document)
http://resources.euroadhoc.com/us/RhIXs9ib company: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Un document
plus
22.06.2012 – 14:21
Takeda Pharmaceutical Company Limited
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - European CHMP adopts positive opinion for teduglutide (Revestive(R)) for patients with short bowel syndrome (SBS) - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications - ...
plus
18.06.2012 – 21:20
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Three-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced results from the 3-year follow-up of the DASISION trial, which show that first-line treatment with SPRYCEL(R) 100 mg results infaster ...
plus

Précédent52535455565758596061Suivant